


# A Novel RNA **Lipid Nanoparticle** Platform: **Gene-Edited CAR T Cells** for Off-the-Shelf Cancer Therapy

*Samuel Clarke, PhD*  
*Director of Product Development*

July 14, 2022



# Next Generation Immune Cell Therapies

## Today


- High response in some advanced blood cancers
- Moderate toxicities
- Limited efficacy in solid tumors
- On-demand manufacturing
  - Autologous
  - Viral Vectors

## Tomorrow


- Additional cancers and earlier lines of therapy
- Reduced toxicities
- Extension to solid tumors
- Off-the-shelf manufacturing
  - **Allogeneic**
  - **Gene-Edited**
  - **Non-Viral Delivery**

# Lipid Nanoparticles for Genetic Engineering of T Cells

Autologous CAR T therapy




"Off-the-shelf" allogeneic CAR T therapy






## T Cell Kit Composition was Selected for Superior Performance in Primary T Cells




We have a **novel lipid library** comprising ionizable lipids and compositions that are **designed** for applications in **vaccines, gene therapy, and cell therapy**.



**Methods:** All component mole ratios maintained with only the ionizable lipid varied. GFP intensity and transfection efficiency was measured via flow cytometry 48 h post treatment. LNP treatment was performed following the T Cell Kit for mRNA on Spark protocol.


# Proof-of-Concept Demonstration of *Ex Vivo* T Cell Engineering

## 1 Gene Expression




2<sup>nd</sup> generation CD19 CAR  
expression

## 2 Gene Knockout




TCR and/or CD52 double  
knockout

## 3 Gene Knockout and Expression




TCR knockout and subsequent  
CAR expression


# 1 LNP Transfection Efficiency and High Cell Viability





## Transfection Efficiency



## Protein Expression




## Viability



Primary T cell




2

# Gene Knockout: Dose-dependent Knockout Efficiency with High Cell Viabilities




# 3 Multi-step Engineering using LNPs: Knockout and Expression



## TCR Knock Out



## CAR Expression








## In Vitro Killing Assay





# For All (and More) Data, Please See Our New App Note!






Spark™



Ignite™



Blaze™



GMP

## GenVoy® Reagents

## Biopharmaceutical Services

Screening

Formulation  
Development

Process  
Development

Scale-up

Technology Transfer & Manufacturing

Chemistry, Manufacturing & Controls (CMC)  
Support

# Acknowledgements

## **PNI Reagents & Delivery Teams**

- Reka Geczy
- Aruna Balgi
- Stella Park
- Rita Zhao
- Anitha Thomas
- Nikita Jain
- Angela Zhang

## **Funding**

- Government of Canada IRAP-NRC Program

## **PNI Departments:**

- Clinical Manufacturing
- Research
- Engineering & Operations
- Preclinical
- Process Development
- Product Development
- Analytical Development
- Quality Control
- Quality Assurance
- Project Management
- RNA Development Services
- Sales and Marketing



 [linkedin.com/company/precision-nanosystems-inc-](https://www.linkedin.com/company/precision-nanosystems-inc-)

 [twitter.com/precisionnano](https://twitter.com/precisionnano)

 [youtube.com/PrecisionNanoSystems](https://www.youtube.com/PrecisionNanoSystems)

# Thank you for listening!

*Questions?*

